Pulse Biosciences, Inc. (NASDAQ: PLSE), a pioneering force in the healthcare sector, stands at the forefront of bioelectric medicine innovation. With a market capitalization of $1.56 billion, the company is gaining attention, particularly with an anticipated potential upside of 12.99%, signaling an intriguing opportunity for investors.

Operating in the medical instruments and supplies industry, Pulse Biosciences is headquartered in Miami, Florida. The company’s portfolio includes groundbreaking products like the CellFX System, which leverages Nanosecond Pulsed-Field Ablation (nsPFA) technology to treat benign skin lesions and soft tissue ablation. This innovative approach is also applied in cardiac treatments via the CellFX…